Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 4. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease 5. Rapid correction of low vitamin D status in nursing home residents
Top Ten Searches
etanercept hypertension chf antiphospholipid fibrosis mrsa scid renal cell rickets counterpulsationYour Article Summary
See Latest ArticlesThe pragmatic use of apomorphine at the end of life
Palliative Medicine, 10/30/09
Dewhurst F et al. – Parkinson's Disease (PD) is an irreversible degenerative neurological disorder with no known cure. Apomorphine is a potent short–acting D1/D2 dopamine agonist administered sub–cutaneously that is used in the treatment of PD. This case highlights its potential benefits for symptom control at the end of life.
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Novel Therapies for Pemphigus Vulgaris: An Overview
Drugs & Aging, 09/21/09
New Anticoagulants in Atrial Fibrillation
Seminars in Thrombosis and Hemostasis, 10/02/09
Antithrombotic medication for stroke prevention
Expert Review of Cardiovascular Therapy , 10/20/09
Today in Neurology...keeping you current
Receive free subspecialty "5-minute updates" via email
Antithrombotic medication for stroke prevention
Expert Review of Cardiovascular Therapy , 10/20/09
Cardiometabolic Risk of Second-Generation Antipsychotic Medications During First-Time Use in Children and Adolescents
JAMA, 10/28/09
Escitalopram and Venlafaxine for the Prophylaxis of Migraine Headache Without Mood Disorders
Clinical Neuropharmacology, 10/02/09
Sponsor
Article Search
Sponsor
Sponsor